Authors

  • Очилов И.А.
  • Анаркулов Р.А.

Keywords:

саркопеническое ожирение, снижение мышечной массы, риск ССЗ, метаболические заболевания.

References

Prado C.M., et al. Sarcopenic obesity: A critical appraisal of the current evidence. Clin Nutr. 20 12;31(5):583–601.

Cruz-Jentoft A.J., et al. Sarcopenia: European consensus on definition and diagnosis. Age and Ageing. 2010;39(4):412–423.

Stenholm S., et al. Sarcopenic obesity: definition, cause and consequences. Curr Opin Clin Nutr Metab Care. 2008;11(6):693–700.

Srikanthan P., et al. Sarcopenia exacerbates obesity-associated insulin resistance and dyslipidemia. Am J Physiol. 2010;298:E357–E363.

Levine M.E., Crimmins E.M. The impact of inflammation on cognitive function in older adults. Am J Geriatr Psychiatry. 2014;22(2):138–147.

Kim T.N., et al. Prevalence and clinical implications of sarcopenic obesity in patients with hypertension. Clin Exp Hypertens. 2013;35(7):565–572.

Wannamethee S.G., et al. Muscle mass and skeletal muscle strength in relation to cardiovascular disease in older men. Age (Dordr). 2014;36(3):9682.

Silva R.M., et al. Association between sarcopenia, obesity and atrial fibrillation. J Geriatr Cardiol. 2020;17(8):479–485.

Zamboni M., et al. Sarcopenic obesity: a new category of obesity in the elderly. Nutr Metab Cardiovasc Dis. 2008;18(5):388–395.

DeFronzo R.A., et al. Type 2 diabetes mellitus and sarcopenic obesity: therapeutic implications. Diabetes Care. 2015;38(4):659–662.